PUBLIC COMPANY
save$MNKDMANNKIND CORP
$MNKD3.8000-3.80%Danbury, CT, USupdated 2d ago
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
community read0 votes
pipeline
3
marketed
1
phase 3
0
catalysts ytd
4
approvals ytd
1
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Marketed1pre_registration1Unknown
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
- phase1A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
- phase3ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
- phase3Afrezza® INHALE-1 Study in Pediatrics
- phase4Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
- phase4INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
- phase1A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers
- phase4Afrezza® Dosing Optimization Study
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Apr 22, 26tax coverPrentiss Christopher B · Chief Financial Officer12,267 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
News
no news has mentioned this company yet
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that